| 18th Jan 2021 7:00 am |
RNS |
Enhertu approved in the US for gastric cancer |
| 15th Jan 2021 7:00 am |
RNS |
Imfinzi new dosing approved in EU |
| 6th Jan 2021 7:00 am |
RNS |
Farxiga granted US Priority Review for CKD |
| 4th Jan 2021 3:00 pm |
RNS |
Total Voting Rights |
| 4th Jan 2021 7:00 am |
RNS |
Atacand divestment in over 70 countries completed |
| 30th Dec 2020 7:00 am |
RNS |
AstraZeneca’s COVID-19 vaccine authorised in UK |
| 29th Dec 2020 7:00 am |
RNS |
Lynparza approved in Japan for three cancers |
| 21st Dec 2020 7:05 am |
RNS |
Tagrisso approved in the US for early lung cancer |
| 21st Dec 2020 7:00 am |
RNS |
Update on US regulatory review of roxadustat |
| 17th Dec 2020 4:00 pm |
RNS |
Director/PDMR Shareholding |
| 16th Dec 2020 6:15 pm |
RNS |
Director/PDMR Shareholding |
| 15th Dec 2020 7:00 am |
RNS |
Imfinzi new dose receives positive EU CHMP opinion |
| 14th Dec 2020 7:05 am |
RNS |
Trastuzumab deruxtecan positive CHMP |
| 14th Dec 2020 7:00 am |
RNS |
Trixeo Aerosphere approved in the EU for COPD |
| 14th Dec 2020 7:00 am |
RNS |
AstraZeneca to acquire Alexion Pharmaceuticals Inc |
| 1st Dec 2020 3:00 pm |
RNS |
Block listing Interim Review |
| 1st Dec 2020 3:00 pm |
RNS |
Total Voting Rights |
| 1st Dec 2020 7:00 am |
RNS |
Crestor to be divested to Grünenthal in Europe |
| 30th Nov 2020 7:00 am |
RNS |
Forxiga approved in Japan for heart failure |
| 23rd Nov 2020 7:00 am |
RNS |
AZD1222 vaccine effective against COVID-19 |
| 20th Nov 2020 7:00 am |
RNS |
Imfinzi new dosing approved in the US |
| 10th Nov 2020 7:00 am |
RNS |
Tezepelumab Phase III trial met primary endpoint |
| 9th Nov 2020 7:00 am |
RNS |
Calquence approved in the EU for CLL |
| 6th Nov 2020 7:00 am |
RNS |
Brilinta approved in the US in stroke |
| 5th Nov 2020 7:15 am |
RNS |
Lynparza approved in the EU for wider ovarian use |
| 5th Nov 2020 7:10 am |
RNS |
Lynparza approved in the EU for prostate cancer |
| 5th Nov 2020 7:05 am |
RNS |
Forxiga approved in the EU for heart failure |
| 5th Nov 2020 7:00 am |
RNS |
AZN: Year-to-date and Q3 2020 results |
| 2nd Nov 2020 3:00 pm |
RNS |
Total Voting Rights |
| 30th Oct 2020 7:00 am |
RNS |
Atacand to be divested in more than 70 countries |
| 29th Oct 2020 7:00 am |
RNS |
Directorate Change |
| 28th Oct 2020 7:03 am |
RNS |
Enhertu US Priority Review in gastric cancer |
| 28th Oct 2020 7:00 am |
RNS |
Forxiga CV outcomes benefit approved in China |
| 20th Oct 2020 7:00 am |
RNS |
Tagrisso adjuvant lung cancer US Priority Review |
| 19th Oct 2020 7:00 am |
RNS |
Forxiga HF receives positive CHMP opinion |
| 19th Oct 2020 7:00 am |
RNS |
Trixeo Aerosphere receives positive CHMP opinion |
| 12th Oct 2020 7:00 am |
RNS |
COVID-19 antibodies advance and get US funding |
| 2nd Oct 2020 11:19 am |
RNS |
Holding(s) in Company |
| 2nd Oct 2020 7:00 am |
RNS |
Farxiga granted US BTD in chronic kidney disease |
| 1st Oct 2020 3:00 pm |
RNS |
Total Voting Rights |
